Trial Profile
A phase II study of PI-88 with dacarbazine in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Muparfostat (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Progen Pharmaceuticals Limited
- 30 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 30 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 05 Mar 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).